Quest Diagnostics: C-Suite Series: 6 Topics for DGX Management

Research evidence excerpt

Quest Diagnostics: C-Suite Series: 6 Topics for DGX Management

Idea

June 9, 2026 06:43 PM GMT

Morgan Stanley & Co. LLCMQuest Diagnostics | North America Erin Wright

Equity Analyst

C-Suite Series: 6 Topics for DGX Erin.Wright1@morganstanley.comMichelle Foley +1 212 761-6137

Research Associate

Michelle.Foley@morganstanley.com +1 212 761-4056

Management Linda Bolduc

Linda.Bolduc@morganstanley.com +1 617 856-8009

We are hosting a conversation with DGX's CEO Jim Davis and Natasha Arya

CFO Sam Samad on Thursday, June 11 at 10am ET. Focus will be Research Associate

Natasha.Arya@morganstanley.com +1 212 761-6294

on the sustainability of strong utilization trends/organic growth/ Craig Hettenbach

sh. gains, Advanced Diagnostics, consumer testing, qtrly EquityCraig.Hettenbach@morganstanley.comAnalyst +1 212 761-6435

progression, AI initiatives and capital deployment. John Y Park

We would greatly appreciate your support in the Healthcare Technology & John.Park@morganstanley.com +1 212 761-4029

Jialin Jin

Distribution category in this year's All-America Extel survey. Thank you so much! - Research Associate

Erin Jay.Jin@morganstanley.com +1 212 761-3913

Quest Diagnostics Inc. (DGX.N, DGX UN)

Healthcare Services & Distribution | United States of

America

Key Questions for Quest Diagnostics management team on Thursday, June 11th

Stock Rating Overweight

at 10am ET: Industry View Attractive

Price target $226.00

1. LT Outlook, Utilization Trends, & Profitability: DGX recently raised 2026 Shr price, close (Jun 8, 2026) $197.21

Mkt cap, curr (mm) $22,144

revenue guidance to +6.8-7.8% which is expected to be largely organic (see our 1Q 52-Week Range $213.39-164.76

earnings recap note here), following robust organic volume growth of ~+11% in 1Q Fiscal Year Ending 12/25 12/26e 12/27e 12/28e